TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06122805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.
Study: NCT05466942

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulse Oximeter, Respiratory Rate, Heart Rate
Description: Measurement of physiological parameters
Study: NCT06375655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team2BF
Description: Team2BF includes 3-4 breastfeeding-supportive messages per time interval, sent weekly from 28 weeks gestation through delivery, daily through 2 weeks postpartum, weekly from 2 to 10 weeks, and then monthly to one year. Other maternal health topics are not addressed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bright By Text
Description: Bright By Text sends 2-4 messages per week from the first trimester through and beyond one year postpartum about a wide range of maternal and child health topics as outlined on their website; 8 messages are specifically about breastfeeding.
Study: NCT06646055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112, Cadonilimab, nab-paclitaxel, gemcitabine
Description: IV infusion, specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112, Cadonilimab, nab-paclitaxel, gemcitabine
Description: IV infusion, specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112, Cadonilimab, nab-paclitaxel, gemcitabine
Description: IV infusion, specified dose on specified days.
Study: NCT06644300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BM230
Description: SC injection
Study: NCT06073314

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative MRI
Description: Patients will be asked to remain in the scanner for an additional 10 minutes while we acquire additional quantitative MR images

Intervention type: DIAGNOSTIC_TEST
Intervention: Reproducibility study
Description: A subset of patients will be invited back for a repeat MRI scan (prior to any treatment for their condition) to help measure reproducibility of our Artificial Intelligence model
Study: NCT03992235

Intervention type: OTHER
Group type: OTHER
Intervention: Chest physiotherapy
Description: All patients will receive chest physiotherapy including Breathing exercise, intensive spirometry use, coughing, ambulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Description: All patients will receive chest physiotherapy including Breathing exercise, intensive spirometry use, coughing, ambulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational material
Description: Exercise brochure with photos and explanations
Study: NCT04799665

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast CT
Description: This is a cross-sectional clinical study to determine the feasibility of breast CT for breast density assessment and association of CT-derived density measures with metabolic syndrome in overweight/obese Mexican-origin women in Southern Arizona. There is no intervention.
Study: NCT05740592

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: micro-osteoperforations ,microincision
Description: Patients in MOPs group will be subjected to minimal 6 MOPs 2mm apart and corticoperforation will be conducted by using drilling bure and only 1 or 2mm bicortical in the mid-palatal suture area. Patients with the piezocision group will be subjected to minimal 3 micro incisions spaced 4mm apart and a piezoelectric device with diamond surgical tip (size: 4 mm, thickness: 0.5mm) will be used.. The MARPE technique comprises the insertion of four bicortical miniscrews adjacent to the mid-palatal suture, being two mesial and two distal to the expanding screw. Each MARPE have two arms and will be fixed to molar band by soldering.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforations ,microincision
Description: Patients in MOPs group will be subjected to minimal 6 MOPs 2mm apart and corticoperforation will be conducted by using drilling bure and only 1 or 2mm bicortical in the mid-palatal suture area. Patients with the piezocision group will be subjected to minimal 3 micro incisions spaced 4mm apart and a piezoelectric device with diamond surgical tip (size: 4 mm, thickness: 0.5mm) will be used.. The MARPE technique comprises the insertion of four bicortical miniscrews adjacent to the mid-palatal suture, being two mesial and two distal to the expanding screw. Each MARPE have two arms and will be fixed to molar band by soldering.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforations ,microincision
Description: Patients in MOPs group will be subjected to minimal 6 MOPs 2mm apart and corticoperforation will be conducted by using drilling bure and only 1 or 2mm bicortical in the mid-palatal suture area. Patients with the piezocision group will be subjected to minimal 3 micro incisions spaced 4mm apart and a piezoelectric device with diamond surgical tip (size: 4 mm, thickness: 0.5mm) will be used.. The MARPE technique comprises the insertion of four bicortical miniscrews adjacent to the mid-palatal suture, being two mesial and two distal to the expanding screw. Each MARPE have two arms and will be fixed to molar band by soldering.
Study: NCT04673903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copenhagen adduction exercise
Description: The Copenhagen Adduction exercise is a simple isolated eccentric partner exercise and doesn't require special equipment and can be performed as a warm up activity on the pitch.
Study: NCT06646055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112, nab-paclitaxel, gemcitabine
Description: IV infusion, specified dose on specified days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel, gemcitabine
Description: IV infusion, specified dose on specified days.
Study: NCT04673903

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual warm up
Description: Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
Study: NCT06163781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood culture prediction tool
Description: Machine learning based predicition tool
Study: NCT06296693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pocket-size lung ultrasound for etiological definition of pneumonia and surveillance of complications in children hospitalized
Description: The investigators will study the diagnostic accuracy of a pocket-size POCUS device vs. CXR for the etiological diagnosis of CAP, in paediatric age. During 1 year, all children aged \>12 months and \<18 years admitted to the Paediatric Department with the diagnosis of CAP on admission will be included. At least 76 participants will be required. Two investigators will perform, independently, a POCUS at admission, daily during hospitalization, 15 days and 1 month after discharge. All children will also undergo a CXR upon admission and whenever necessary. A third investigator will classify the CXR independently. It will be used the General Electrics Vscan AirTM®, with Bluetooth connection to smartphone/tablet. It will be collected the systematized description of POCUS and CXR, sociodemographic, clinical and therapeutic variables.
Study: NCT05932680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Off Drug Surveillance
Description: After stopping teclistamab, participants will be monitored monthly by standard serum paraprotein studies for disease progression. Participants will resume teclistamab at time of disease progression. After Teclistamab therapy re-initiation on-study, monthly response assessments and data for other study endpoints will be obtained. All participants will undergo peripheral blood collection for correlative research studies at baseline and every two months on-study. Participants who enroll on the biomarker sub-study will undergo bone marrow examination and peripheral blood collection for correlative studies at study entry, at time of disease progression and at six months from enrollment.
Study: NCT06153212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Membrane placement with bone grafting
Description: The diseased dental implant will be cleaned and the bone defect will be filled with bone graft and covered by a membrane.
Study: NCT06153212

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Membrane placement with bone grafting
Description: The diseased dental implant will be cleaned and the bone defect will be filled with bone graft and covered by a membrane.
Study: NCT05127772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
Study: NCT05408065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Hexacetonide and hyaluronic acid
Description: infiltration under fluoroscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Hexacetonide
Description: infiltration under fluoroscopy
Study: NCT05127772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
Study: NCT05638984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine Injection
Description: Injection site citabine, 10 mg/ bottle, 10 mg/d, Q3W, D1-D5 intravenous infusion; Tirelizumab injection 200mg D5 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirelizumab
Description: 10ml: 100mg / 1 bottle, 200mg, Q3W, D1 i. v. infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tirelizumab
Description: 10ml: 100mg / 1 bottle, 200mg, Q3W, D1 i. v. infusion.
Study: NCT06016660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Resistance exercise, Neuromuscular electrical stimulation, and Transcutaneous electrical stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Resistance exercise, Neuromuscular electrical stimulation, and Transcutaneous electrical stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Resistance exercise, Neuromuscular electrical stimulation, and Transcutaneous electrical stimulation
Study: NCT05607758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StressProffen©™
Description: An app-based program for stress management consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
Study: NCT05750667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cascade screening
Description: FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cascade screening
Description: FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
Study: NCT05315258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp
Description: Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.
Study: NCT05965570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Oral tablets.
Study: NCT06465901

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower
Description: Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower
Description: Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative wound wash (e.g. Granudacyn)
Description: Intraoperative wound wash (e.g. Granudacyn)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative wound wash (e.g. Granudacyn)
Description: Intraoperative wound wash (e.g. Granudacyn)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DACC surgical wound dressing (e.g. Leukomed Sorbact)
Description: DACC surgical wound dressing (e.g. Leukomed Sorbact)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DACC surgical wound dressing (e.g. Leukomed Sorbact)
Description: DACC surgical wound dressing (e.g. Leukomed Sorbact)
Study: NCT05697692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin sodium
Description: Lung transplantation on central veno-arterial ECMO with standard additional heparin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lung transplantation on central veno-arterial ECMO without additional heparin
Study: NCT06470464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin)
Description: The oral dose of thalidomide is 1.5-2.5mg/kg/d daily (maximum 28g). Each cycle lasts for 21 days (every three weeks), and if treatment parameters are met as described in the study, cycle two and subsequent cycles begin on day 22. Treatment will be discontinued if there is drug-related dose-limiting toxicity or disease progression. Tumor response assessment will be repeated using AFP and LDH every one cycle and imaging examination every two cycles. Children who complete the trial may continue this regimen or undergo surgery or radiation therapy if their disease goes into remission.
Study: NCT06257121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OSMS position management
Description: Patient position management in real time during radiation using an optical Surface Management System (OSMS) (Vision RT)
Study: NCT05770076

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic lysate (postbiotic and metabiotic)
Description: Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04858126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECOM cardiac output
Description: Measure cardiac output during perioperative period and compare to pulmonary artery catheter thermal dilution cardiac output measurement.
Study: NCT06046053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Vaginal Film with Square Corners
Description: 2 x 2 placebo vaginal film with square corners

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Vaginal Film with Rounded Corners
Description: 2 x 2 placebo vaginal film with rounded corners
Study: NCT04624659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat Tablets Low dose
Description: 200 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat Tablets High dose
Description: 400 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablets
Description: Placebo once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat Tablets
Description: Selected dose once daily
Study: NCT06003998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 2 weekly IP irinotecan (max 12 cycles), dose 75 mg flat dose
Study: NCT04317846

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous administration of vasodilatory drugs
Description: Administration of the vasodilatory drugs in a different pattern than intra-arterially

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous administration of vasodilatory drugs
Description: Administration of the vasodilatory drugs in a different pattern than intra-arterially

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous administration of vasodilatory drugs
Description: Administration of the vasodilatory drugs in a different pattern than intra-arterially
Study: NCT05644418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow Controlled Ventilation (FCV)
Description: FCV is started with the same settings as PCV (PEEP, Ppeak, FiO2) and after 30 minutes FCV is optimized concerning the driving pressure and PEEP using the dynamic compliance. After a total of 60 minutes the flow is adjusted based on the arterial blood gas.
Study: NCT05419258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UPLUG Hemodialysis Connection Device
Description: use of the device UPLUG during 1 month
Study: NCT06433739

Intervention type: OTHER
Intervention: standardized algorithm
Description: standardized algorithm for the correct selection of peripheral venous catheters

Intervention type: OTHER
Intervention: standardized algorithm
Description: standardized algorithm for the correct selection of peripheral venous catheters
Study: NCT06501235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: An adaptation of the Robles and Peralta's (2010) stress management program will be followed. This program includes key techniques from the CBT approach, such as deactivation techniques, cognitive restructuring, and assertiveness training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtue-Based Intervention (VBI)
Description: A Well-being Training based on Contemplative Practices (WTCP) (Cebolla \& Alvear, 2019; Alvear \& Cebolla, 2023) will be followed. WTCP combines mindfulness practices with various activities based on virtues such as gratitude, altruism, or compassion. This program focuses on generative or constructive meditations, and puts special emphasis on virtuous actions, emotion regulation (both positive and negative emotions) and compassion, and includes strategies from positive psychology, such as strengths-based interventions, savoring, kindness, or the three good things.
Study: NCT06003998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: FOLFOX-4 regimens consist of 85 mg/m2 oxaliplatin plus 200 mg/m2 LV and 5-FU 400 mg/m2 bolus on day 1 followed by 1600 mg/m2 5-FU as a 46-h infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab according to standard of care
Study: NCT05418946

Intervention type: DRUG
Intervention: Dapagliflozin 10mg
Description: Treatment of T2D and cardio-renal prevention
Study: NCT06244966

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV diagnostic testing
Description: Finger-prick capillary blood will be tested alongside venous blood
Study: NCT06514612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers
Description: STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers
Description: Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers
Study: NCT06510361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Humanized IgG1 bispecific antibody, 5 or 60 mL vial, via subcutaneous (under the skin) injection per protocol.
Study: NCT06523634

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: 5 fractions of SBRT to the prostate bed with or without whole pelvic radiotherapy Treatment every other day.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SOC RT
Description: Standard salvage radiotherapy to the prostate bed with or without whole pelvic radiotherapy. Each participating centre can specify upfront which RT schedule will be used in the control arm, with the choice between the following schedules:~* Hypofractionated: 20 fractions (Daily treatment (OTT 4-5 weeks))~* Normofractionated: 32-35 fractions (Daily treatment (OTT 7-8 weeks))